EAU Update on Bladder Cancer and Renal Cell Cancer
We are currently re-organising and making new arrangements. Once we finalise preparations, we will post the information here accordingly.
After extensive consideration in light of the COVID-19 situation, we have made the difficult but necessary decision to postpone the BCa-RCC20 meeting until further notice.
Our current primary goal is to prevent putting anyone’s health and safety at risk.
At present, we are re-organising and making new arrangements. Once we finalise preparations, we will post the information here accordingly. If you already registered, your registration will be valid for the new dates. If you have any questions, please do not hesitate to contact us. We express our gratitude for your continued support.
Faculty-led interactive sessions
Expert faculty will present and examine real-life case discussions and scenarios that look into the various facets of clinical management.
The scientific programme of BCa-RCC20 was designed to educate urologists on the latest immuno-oncological treatment options for renal and bladder cancer patients. Urologists should be familiar with the emerging medical treatments and their impact on their patients.
BCa-RCC20 measures your level of knowledge on renal and bladder cancer before and after the meeting with an online test. During the meeting, you will regularly be asked to vote on treatment options and case discussions.